

# Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy

Deepika Singhal, Roopali Desai, Sejal Desai, Manisha Shastri, Deepak Saxena

Department of Ophthalmology, Surat Municipal Institute of Medical Education and Research, Surat, Indian Institute of Public Health, Gandhinagar, India

## ABSTRACT

**Objective:** To study the effect of brimonidine on intraocular pressure (IOP) following capsulotomy among Indian subjects. **Materials and Methods:** The study was a nonrandomized trial with open label. **Results:** 80% of the subjects showed a decrease in IOP after instilling 0.2% brimonidine (1 hour pre capsulotomy). No such decrease was observed in control. After 1 and 4 h post capsulotomy a statistically significant decrease in IOP ranging between 1–10 mmHg was found in 73.3% of the treatment group. **Conclusions:** In the present study 0.2% brimonidine has been proven effective to counteract the increase in IOP following Nd-YAG laser capsulotomy in Indian setting.

**Key words:** Brimonidine, intraocular pressure, Nd-YAG laser capsulotomy, posterior capsular opacification

## INTRODUCTION

WHO defines blindness as visual acuity less than 3/60 (Snellen) or inability to count fingers in day light at a distance of 3 m.<sup>[1]</sup> Eighty percent of blindness is avoidable, i.e., readily treatable and/or preventable.<sup>[1]</sup>

Major cause of blindness currently in India is cataract (62.6%).<sup>[2]</sup> Majority of the cataract surgeries performed nowadays is by extra capsular cataract extraction (ECCE).<sup>[3]</sup> Chances of posterior capsular opacification (PCO) remain high with ECCE with or without intraocular lens (IOL) and hence it is one of the most important complication of ECCE. It leads to decrease in vision post-operatively to an extent

that it diminishes more than pre-operative state.<sup>[4]</sup> Although, overall incidence of PCO is now rapidly decreasing – from 50% in the 1980s and early 1990s to less than 10% currently.<sup>[4]</sup> A noninvasive method of dealing with PCO is Nd-YAG laser capsulotomy. But Nd-YAG laser has its own problems like corneal haze, uveitis, hyphema, lens pits, and retinal detachment but the most consistent complication is the post-capsulotomy rise in intraocular pressure (IOP).<sup>[5]</sup> Rise in IOP is probably caused by clogging of the trabeculum with debris.<sup>[7]</sup> This is maximum after 2–4 hours of procedure.<sup>[6]</sup>

Drug brimonidine is usually used in the treatment of glaucoma as it lowers the IOP and reduces risk of progression and loss of vision. Mode of action is by  $\alpha_2$ -adrenergic receptor agonist, thus resulting in lowering of IOP.<sup>[7-9]</sup> It has dual mechanism of action – firstly it decreases the aqueous humor formation and secondly it increases the uveoscleral outflow.<sup>[9]</sup> Brimonidine is proven safe and well-tolerated.<sup>[7,8,10]</sup> Ciprofloxacin is a synthetic chemotherapeutic and is a second-generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, thereby stopping DNA and protein synthesis.<sup>[11]</sup> Ciprofloxacin

| Access this article online                                                          |                                                                        |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Quick Response Code:                                                                | Website:<br><a href="http://www.jpharmacol.com">www.jpharmacol.com</a> |
|  | DOI:<br>10.4103/0976-500X.81902                                        |

## Address for correspondence:

Deepak Saxena, Indian Institute of Public Health, Gandhinagar - Gujarat, India. E-mail: [ddeepak72@yahoo.com](mailto:ddeepak72@yahoo.com)

does not have any documented effect on IOP. The present study documents the effect of brimonidine on the prevention of this post-procedural spike of IOP in the Indian subjects.

## MATERIAL AND METHODS

Ethical clearance was obtained to carry out this open-label, nonrandomized trial. Study subjects who consented to be a part of the study were selected and matched in terms of age and sex. The inclusion criteria in the study was non-glaucomatous subjects who presented with dimness of vision following PCO after ECCE, advised for Nd-YAG laser posterior capsulotomy at Surat Municipal Institute of Medical Education and Research (SMIMER). Exclusion criteria included subjects who were glaucomatous, high myopic, having corneal opacities and uveitis. Those subjects who had not consented were also excluded from the present study.

A purposive sample of 60 subjects (60 eyes), as per the inclusion criteria, participated in the study. Purpose and procedures were explained and after obtaining written informed consent, they were allocated in two groups:

Group A: Subjects who were instilled with 0.2% brimonidine<sup>[7-9]</sup>  
Group B: Treated with 0.3% ciprofloxacin

The pre-procedural assessment, sociodemographic profile, clinical history, and clinical ophthalmic examination of the subjects were recorded in a pretested and semi-open-ended performa. Ophthalmic examination included:

1. Torch light examination of eye
2. Visual acuity by Snellen's chart and vision with pin hole
3. Subjective refraction
4. Fundoscopy (direct and indirect)
5. IOP measurement

Base-line IOP was recorded by Goldmann Applanation tonometer. Before an hour of the capsulotomy, subjects from Group A were instilled with one drop of brimonidine 0.2% [pharmacological name: 5-bromo-6(2-imidazolidinylideneamino) quinoxaline-L-tartrate and trade name: Alphagan]. However in the subjects belonging to Group B, one drop of ciprofloxacin 0.3% was instilled. IOP was again recorded after 1 hour of instillation of drug (pre-laser post-drop IOP). YAG laser for PCO was done in both the groups under topical anesthesia. The power setting of the YAG machine for both the groups was between 2 to 3 mJ per pulse and the number of shots ranged from 2 to 4 per patient depending upon the thickness of PCO.

Immediately post-capsulotomy, 0.2% of brimonidine and 0.3% of ciprofloxacin were again instilled in subjects of Group A and Group B, respectively. IOP was recorded after 1 and 4 hours to document the effect of brimonidine in terms of change in IOP. Data were recorded and analyzed by the help of Epi 6.04.

## RESULTS

Majority of the subjects in both groups belonged to the age group of 41-60 years; this can be attributed to the higher incidence of cataract in this age group.<sup>2</sup> Out of total 60 subjects, who participated in the study, 26 (43.3%) were males and 34 (56.7%) were females.

Pre treatment (baseline) IOP was recorded one hour before the YAG laser capsulotomy and majority of subjects in both the groups had IOP between 10-19 mmHg. None of them had an IOP above 20 mmHg hence adhering to the inclusion criteria of being non glaucomatous at the time of capsulotomy [Table 1].

Post Brimonidine Pre Laser IOP i.e. IOP after one hour of instillation of Brimonidine in Group A revealed a fall in IOP prior to YAG laser capsulotomy [Table 2]. A decrease in the IOP was noted in 24 subjects of Group A. However no such decrease in IOP was observed in Group-B.

Immediately post capsulotomy 0.2% of brimonidine and 0.3% of ciprofloxacin were again instilled in subjects of Group-A and Group-B respectively [Table 3].

Following observations were made:

Post capsulotomy after 1hour, out of 30 subjects in Group A, rise in IOP was seen in only 1(3.3%). However Group B 14(46.6%) subjects had raised IOP. This rise ranged from 0-10 mmHg. Amongst subjects of Group-A, 50% had a fall of 1-5mmHg in IOP whereas no such fall was seen in subjects of

**Table 1: Pretreatment (baseline) intraocular pressure**

| IOP (mmHg) | No. of subjects |         | Total      |
|------------|-----------------|---------|------------|
|            | Group A         | Group B |            |
| <10        | 02 (6.66)       | 00      | 02 (3.33)  |
| 10-15      | 14 (46.67)      | 18 (60) | 32 (53.33) |
| 16-19      | 14(46.67)       | 12(40)  | 26 (43.34) |
| 20-25      | 00              | 00      | 00         |
| >25        | 00              | 00      | 00         |
| Total      | 30              | 30      | 60         |

Figures in the parenthesis indicates percentage

**Table 2: IOP 1 h post brimonidine (prelaser IOP)**

| Percentage fall in IOP | No. of subjects |          |
|------------------------|-----------------|----------|
|                        | Group A         | Group B  |
| 0-10                   | 0               | 00 (00)  |
| 11-20                  | 10 (33.3)       | 00 (00)  |
| 21-30                  | 10 (33.3)       | 00 (00)  |
| 31-40                  | 1 (3.4)         | 00 (00)  |
| >40                    | 3 (10)          | 00 (00)  |
| No change in IOP       | 6 (20)          | 30 (100) |
| Total                  | 30 (100)        | 30 (100) |

Figures in the parenthesis indicates percentage

**Table 3: Intraocular pressure changes after laser treatment**

| Intraocular pressure in mmHg | No. of subjects in Group A |              | No. of subjects in Group B |              |
|------------------------------|----------------------------|--------------|----------------------------|--------------|
|                              | After 1 hour               | After 4 hour | After 1 hour               | After 4 hour |
| Rise in pressure             |                            |              |                            |              |
| 1–5                          | 1                          | 0            | 9                          | 6            |
| 6–10                         | 0                          | 1            | 5                          | 18           |
| >10                          | 0                          | 0            | 0                          | 0            |
| Fall in pressure             |                            |              |                            |              |
| 1–5                          | 15                         | 12           | 0                          | 0            |
| 6–10                         | 10                         | 10           | 0                          | 0            |
| >10                          | 0                          | 5            | 0                          | 0            |
| No change in pressure        | 4                          | 2            | 16                         | 6            |
| Total                        | 30                         | 30           | 30                         | 30           |

For applying chi square ( $\chi^2$ ) test fall in pressure and no change in pressure has been clubbed together

Group-B. No change in IOP was seen in 13.3% of subjects from Group A and 16 (53.3%) subjects of Group B. Observations in change of IOP after 1 h of the intervention were found to be highly significant with a *P* value of 0.00002.

After 4 h of YAG Laser capsulotomy IOP was raised in only 1 (3.3%) out of 30 subjects in Group A. On the contrary in subjects of Group B, 24(80 %) subjects had raised IOP. This rise ranged from 1-5 mm in 6 subjects (20%) and 6–10 mmHg in 18 (60%) subjects. In Group A, the proportions of subject having a fall of IOP between 1-10 mm was 73.3 % and 16.6% of subjects had a fall of more than 10 mm. However no such fall in IOP was seen in subjects from Group B. The observations after 4 h of the intervention were found to be highly significant with a *P* value of 0.000023.

## DISCUSSION

Brimonidine has been tried to decrease the rise in IOP after YAG laser capsulotomy by several researchers.<sup>[12,13]</sup> In a study by Gartaganis *et al.*, a significant mean percent reduction in IOP was found after 0.2% brimonidine instillation 1 h pre capsulotomy and immediately post capsulotomy. However in the present study, when one drop of 0.2% brimonidine was instilled 1 hour pre-capsulotomy and immediately after Nd-YAG laser capsulotomy, IOP elevations were prevented. Yeom *et al.* had also documented similar observations where IOP decreased from the baseline in the group who were instilled with brimonidine.

But in his study, decrease in IOP was significant after third postoperative hour (*P*<0.05), while the control group exhibited an increase in IOP. Present study also documents a decrease in IOP after 1 and 4 hour in Group A who were instilled with brimonidine. Thus present study provide substantial evidence in favor of brimonidine for prevention of acute rise in IOP after Nd:YAG laser posterior capsulotomy among Indian patients.

## REFERENCES

- Global Facts according to WHO estimates, Available from: <http://www.who.int/mediacentre/factsheets/fs282/en/index.html>.
- National Program for Control of Blindness, Ministry of Health and Family Welfare, Government of India. Available from: <http://npwb.nic.in>.
- Gogate PM, Deshpande M, Wormald RP. Is manual small incision cataract surgery affordable in the developing countries? A cost comparison with extra capsular cataract extraction. *Br J Ophthalmol* 2003;87:843-6.
- Pandey SK, Apple DJ, Werner L, Maloof AJ, Milverton EJ. Posterior Capsule Opacification: A Review of the Aetiopathogenesis, Experimental and Clinical Studies and Factors for Prevention. *Indian J Ophthalmol* 2004;52:99-112. Available from: <http://www.ijo.in/text.asp?2004/52/2/99/14613>. [Last cited on 2010 Nov 21].
- Kraff CM, Saunders DR, Liebermann HL. Intraocular pressure and the corneal endothelium after Nd:Yag laser posterior capsulotomy. Relative effects of aphakia and pseudophakia. *Arch Ophthalmol* 1985;103:511-4.
- Schubert HD. A history of intraocular pressure rise with reference to the Nd:YAG laser. *Surv Ophthalmol* 1985;30:168-72.
- Allergan. Alphagan (Brimonidine Tartarate) 0.2% product monograph. Medical and Healthcare products regulatory Agency. Available from: <http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con082091.pdf>. [Last accessed on 2010 Oct 12].
- Zimmermann TJ. Brimonidine: An alpha adrenergic blocking agent for the treatment of glaucoma.
- Burke. Brimonidine's Basic pharmacology(conference) speaker at the 2<sup>nd</sup> International Glaucoma symposium. A new era Glaucoma management, March 1998.
- Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. *Ther Clin Risk Manag* 2006;2:337-46.
- Nelson JM, Chiller TM, Powers JH, Angulo FJ. "Fluoroquinolone-resistant *Campylobacter* species and the withdrawal of fluoroquinolones from use in poultry: A public health success story. *Clin Infect Dis* 2007;44:977-80.
- Gartaganis SP, Mela EK, Katsimpris JM, Petropoulos JK, Karamanos NK, Koliopoulos JX. Use of topical brimonidine to prevent intraocular pressure elevations following Nd:YAG-laser posterior capsulotomy. *Ophthalmic Surg Lasers* 1999;30:647-52.
- Yeom HY, Lee JH, Hong YJ, Seong GJ. Brimonidine 0.2% versus brimonidine Purite 0.15%: Prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. *J Ocul Pharmacol Ther* 2006;22:176-81.

**How to cite this article:** Singhal D, Desai R, Desai S, Shastri M, Saxena D. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy. *J Pharmacol Pharmacother* 2011;2:104-6.

**Source of Support:** Nil, **Conflict of Interest:** None declared.